The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Synergy of EGFR and AURKA Inhibitors in KRAS -mutated Non–small Cell Lung Cancers
Open accessPublished version of a preprint
Abstract
The most common oncogenic driver mutations for non–small cell lung cancer (NSCLC) activate EGFR or KRAS. Clinical trials exploring treatments for EGFR- or KRAS-mutated (EGFRmut or KRASmut) cancers have focused on small-molecule inhibitors targeting the driver mutations. Typically, these inhibitors perform more effectively based on combination with either chemotherapies, or other targeted therapies. For EGFRmut NSCLC, a combination of inhibitors of EGFR and Aurora-A kinase (AURKA), an oncogene commonly overexpressed in solid tumors, has shown promising activity in clinical trials. Interestingly, a number of recent studies have indicated that EGFR activity supports overall viability of tumors lacking EGFR mutations, and AURKA expression is abundant in KRASmut cell lines. In this study, we have evaluated dual inhibition of EGFR and AURKA in KRASmut NSCLC models. These data demonstrate synergy between the EGFR inhibitor erlotinib and the AURKA inhibitor alisertib in reducing cell viability and clonogenic capacity in vitro, associated with reduced activity of EGFR pathway effectors, accumulation of enhanced aneuploid cell populations, and elevated cell death. Importantly, the erlotinib-alisertib combination also synergistically reduces xenograft growth in vivo. Analysis of signaling pathways demonstrated that the combination of erlotinib and alisertib was more effective than single-agent treatments at reducing activity of EGFR and pathway effectors following either brief or extended administration of the drugs. In sum, this study indicates value of inhibiting EGFR in KRASmut NSCLC, and suggests the specific value of dual inhibition of AURKA and EGFR in these tumors. Significance: The introduction of specific KRAS G12C inhibitors to the clinical practice in lung cancer has opened up opportunities that did not exist before. However, G12C alterations are only a subtype of all KRAS mutations observed. Given the high expression of AURKA in KRASmut NSCLC, our study could point to a potential therapeutic option for this subgroup of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Inhibition of AURKA could sensitize KRAS-mutant CRC and NSCLC to EGFR-targeted therapy [135, 136].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [135]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · cited 1×
“…studies of AURKA and EGFR inhibition in KRAS-mutated (KRAS mut ) tumors, we first analyzed genomic and transcrip-tomicdataavailablethroughcBioportal(37). mRNAandproteinlevelsofEGFR were elevated in EGFR-mutated (EGFR mut ) versus KRAS mut tumors (median Z-scores 0.53 vs. − 0.14 for mRNA, P -value…”
InfluentialDrug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · cited 1×
“The software CompuSyn was used to determine IC 50 valuesforerlotinibandalisertib,andsynergybytheChou-Talalaymethod (30).”
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
The biology and management of non-small cell lung cancer
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302
Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910231 · Cited by 2,823
Self-citationK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027 · cited 1×
“Although EGFR activates numerous downstream signaling effectors, including FAK, SRC, PLC γ , STATs, and others (46, 47), RAS has often been proposed to represent the most important mediator of EGFR biological activity.”
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 1×
“For example, in colorectal cancers overexpressing EGFR, the presence of a strongly activating KRAS mutation eliminates the effectiveness of EGFR-targeting antibodies, even in tumors with highly overexpressed EGFR (48, 49).”
Cited by
Aurora kinases signaling in cancer: from molecular perception to targeted therapies
Vats, P., Saini, C., Baweja, B., Srivastava, S. K., Kumar, A., Kushwah, A. S., & Nema, R. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02353-3 · Cited by 59
“The rationale lies in AURKA’ s role in promoting mitotic survival and bypassing KRAS-induced checkpoint failures [270].”
Chung, S., Sperier, E., Graciano, K., Hu, X. P., Guo, H., & Xu, J. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108633 · Cited by 22
AURKA Suppresses Ferroptosis via the KEAP1/NRF2/HO‑1 Axis in EGFR-Mutant Lung Adenocarcinoma
Huang, Y., Liu, G., Zhu, L., & Zhang, J.-H. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl41293 · Cited by 10
“This seemingly paradoxical observation may reflect the dependency of EGFR-mutant tumors on EGFR-driven signaling, which could suppress alternative oncogenic pathways such as those involving AURKA [61,62].”
Jameson, N. M., Kim, D., Lee, C., Skrable, B., Shea, A., Guo, X., Izadi, H., Abed, M., Harismendy, O., Ma, J., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0411 · Cited by 9
Differential Response and Resistance to KRAS-Targeted Therapy
Liu, Z., Lenz, H., Yu, J., & Zhang, L. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23908 · Cited by 7
Metadata
- Authors
- Bagnyukova, T., Egleston, B. L., Pavlov, V. A., Serebriiskii, I. G., Golemis, E. A., & Borghaei, H.
- Affiliations
- Fox Chase Cancer Center (US)
- Corresponding author
- Borghaei, Hossein
- ORCID
- Venue
- Cancer Research Communications
- Published
- 2024-05-08
- Volume
- 4
- Issue
- 5
- Pages
- 1227-1239
- ISSN
- 2767-9764 (ISSN-L)
- PMC
- PMC11078142
- OpenAlex
- W4394941922
- Cited by
- 14
- References
- 67
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 1
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancer Research Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- TUScholarShare (Temple University) (submittedVersion, cc-by)
- Funders
- HHS | NIH | National Cancer Institute (P30 CA006927)
- William Wikoff Smith Charitable Trust
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- non-small cell lung cancer, KRAS mutation, EGFR inhibition, erlotinib, alisertib, combination therapy, drug synergy, aneuploidy, clonogenicity, xenograft tumor growth, KRAS G12C inhibitors
- MeSH terms
- Erlotinib Hydrochloride, Animals, Antineoplastic Combined Chemotherapy Protocols, Azepines, Carcinoma, Non-Small-Cell Lung, Drug Synergism, Humans, Lung Neoplasms, Mutation, Pyrimidines, Proto-Oncogene Proteins p21(ras), Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, Aurora Kinase A, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synergy of EGFR and AURKA Inhibitors in KRAS -mutated Non–small Cell Lung Cancers. https://app.cochat.ai/papers/10.1158/2767-9764.crc-23-0482
- The paper
- Bagnyukova, T., Egleston, B. L., Pavlov, V. A., Serebriiskii, I. G., Golemis, E. A., & Borghaei, H. (2024). Synergy of EGFR and AURKA Inhibitors in KRAS -mutated Non–small Cell Lung Cancers. Cancer Research Communications. https://doi.org/10.1158/2767-9764.crc-23-0482
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.